<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23392" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Immunoglobulin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Justiz Vaillant</surname>
            <given-names>Angel A.</given-names>
          </name>
          <aff>University of the West Indies</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jamal</surname>
            <given-names>Zohaib</given-names>
          </name>
          <aff>Rawalpindi Medical University, Rawalpindi</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ramphul</surname>
            <given-names>Kamleshun</given-names>
          </name>
          <aff>Shanghai Jiao Tong University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Angel Justiz Vaillant declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Zohaib Jamal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kamleshun Ramphul declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23392.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Immunoglobulins (Ig) or antibodies are glycoproteins produced by plasma cells. B cells are instructed by specific immunogens, for example, bacterial proteins, to differentiate into plasma cells, which are protein-making cells that participate in humoral immune responses against bacteria, viruses, fungi, parasites, cellular antigens, chemicals, and synthetic substances. The immunogen or antigen reacts with a B-cell receptor (BCR) on the cell surface of B lymphocytes. A signal is produced that directs the activation of transcription factors to stimulate the synthesis of antibodies, which are highly specific for the immunogen that stimulated the B cell. Furthermore, one clone of a B cell makes an immunoglobulin (specificity). Besides, the immune system remembers the antigens that caused a previous reaction (memory) due to the development of memory B cells. These are intermediate, differentiated B cells that can quickly become plasma cells. In addition, circulating antibodies recognize antigens in tissue fluids and serum. This activity describes the physiology and pathophysiology of immunoglobulins.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the function of immunoglobulins.</p></list-item><list-item><p>Outline disorders associated with immunoglobulin deficiencies.</p></list-item><list-item><p>Summarize the presentation of patients with immunoglobulin deficiency.</p></list-item><list-item><p>Explain the importance of improving care coordination amongst the interprofessional team to enhance care delivery for patients with immunoglobulin deficiency.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23392&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23392">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23392.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Immunoglobulins (Ig) or antibodies are glycoproteins produced by plasma cells. B cells are instructed by specific immunogens, for example, bacterial proteins, to differentiate into plasma cells. Plasma cells are protein-making cells participating in humoral immune responses against bacteria, viruses, fungi, parasites, cellular antigens, chemicals, and synthetic substances.<xref ref-type="bibr" rid="article-23392.r1">[1]</xref>&#x000a0;Immunoglobulins constitute about 20% of the protein in plasma.</p>
        <p>The immunogen or antigen reacts with a B-cell receptor (BCR) on the cell surface of B lymphocytes. A signal is produced that directs the activation of transcription factors to stimulate the synthesis of antibodies, which are highly specific for the immunogen that stimulated the B cell. Furthermore, one clone of a B cell makes an immunoglobulin (specificity). The immune system remembers the antigens that caused a previous reaction (memory) due to the development of memory B cells. These are intermediate, differentiated B cells that can quickly become plasma cells. Circulating antibodies recognize antigens in tissue fluids and serum.</p>
        <p>The following are five types of immunoglobulins in humans:</p>
        <list list-type="order">
          <list-item>
            <p>IgM</p>
          </list-item>
          <list-item>
            <p>IgG</p>
          </list-item>
          <list-item>
            <p>IgA</p>
          </list-item>
          <list-item>
            <p>IgE</p>
          </list-item>
          <list-item>
            <p>IgD<xref ref-type="bibr" rid="article-23392.r2">[2]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23392.s3" sec-type="Function">
        <title>Function</title>
        <p>
<bold>Basic Immunoglobulin Structure and Function</bold>
</p>
        <p>Antibodies or immunoglobulins have two light chains and two heavy chains in a light-heavy-heavy-light structure arrangement. The heavy chains differ among classes. They have one Fc region that mediates biological functions (e.g., the binding capacity to cellular receptors) and a Fab region containing antigen-binding sites. The chains are folded into regions called domains. There are 4 or 5 domains in the heavy chain, depending on their class, and two domains in the light chain. The hypervariable regions (HRR) contain the antigen-binding sites. There are three HRRs in the V&#x000a0;domains of each light and heavy chain. These fold into regions that produce two antigen-binding sites at the tip of each monomer. All antibodies exhibit one or more functions (bifunctional), including activation of the complement system, opsonization of microbes to be easily phagocytosed, prevention of attachment of the microbes to mucosal surfaces, and neutralization of toxins and viruses.<xref ref-type="bibr" rid="article-23392.r1">[1]</xref></p>
        <p>
<bold>Immunoglobulin M</bold>
</p>
        <p>IgM<bold>&#x000a0;</bold>has a molecular weight of 970 Kd and an average serum concentration of 1.5 mg/ml. It is mainly produced in the primary immune response to infectious agents or antigens. It is a pentamer and activates the classical pathway of the complement system. IgM is regarded as a potent agglutinin (e.g., anti-A and anti-B isoagglutinin present in type B and type A blood, respectively), and a monomer of IgM is used as a B cell receptor (BCR).<xref ref-type="bibr" rid="article-23392.r3">[3]</xref></p>
        <p>
<bold>Immunoglobulin G</bold>
</p>
        <p>IgG&#x000a0;is a monomer with an approximate molecular weight of 146 Kd and a serum concentration of 9.0 mg/mL. IgG is said to be divalent, i.e., it has two identical antigen-binding sites that comprise 2&#x000a0;L chains and&#x000a0;2 H chains joined by disulfide bonds. IgG is synthesized mostly in the secondary immune response to pathogens. IgG can activate the classical pathway of the complement system, and it also is highly protective. The four subclasses of IgG include IgG1, IgG2, IgG3, and IgG4. IgG1 is around 65% of the total IgG. IgG2 forms an important host defense against bacteria that are encapsulated. IgG is the only immunoglobulin that crosses the placenta as its Fc portion binds to the receptors present on the surface of the placenta, protecting the neonate from infectious diseases.<xref ref-type="bibr" rid="article-23392.r4">[4]</xref>&#x000a0;IgG is thus the most abundant&#x000a0;antibody present in newborns.</p>
        <p>
<bold>Immunoglobulin A</bold>
</p>
        <p>IgA&#x000a0;appears in 2 different molecular structures: monomeric (serum) and dimeric structure (secretory). The serum IgA has a molecular weight of 160 Kd and a serum concentration of 3 mg/mL. Secretory IgA (sIgA) has a molecular weight of 385 Kd and a mean serum concentration of 0.05 mg/mL. IgA is the major antibody in secretions found in saliva, tears, colostrum, intestinal, genital tract, and respiratory secretions.</p>
        <p>It appears in mucosa membranes as a dimer (with a J chain when secreted) and protects the epithelial surfaces of the&#x000a0;digestive, respiratory,&#x000a0; and genitourinary systems. IgA possesses a secretory component that prevents its enzymatic digestion. It activates the alternative pathway of activation of the complement system.<xref ref-type="bibr" rid="article-23392.r5">[5]</xref></p>
        <p>
<bold>Immunoglobulin E</bold>
</p>
        <p>IgE&#x000a0;is a monomer. It has a molecular weight of 188 Kd and a serum concentration of 0.00005 mg/mL. It protects against parasites and binds to high-affinity receptors on mast cells and basophils, causing allergic reactions.<xref ref-type="bibr" rid="article-23392.r6">[6]</xref><xref ref-type="bibr" rid="article-23392.r7">[7]</xref><xref ref-type="bibr" rid="article-23392.r8">[8]</xref>&#x000a0;IgE is&#x000a0;considered the most important host defense against different parasitic infections, including<italic toggle="yes"> Strongyloides&#x000a0;stercoralis, Trichinella spiralis, Ascaris lumbricoides, and hookworms Necator americanus and Ancylostoma&#x000a0;duodenale.</italic></p>
        <p>
<bold>Immunoglobulin D</bold>
</p>
        <p>IgD&#x000a0;is&#x000a0;a monomer with a molecular weight of 184 Kd. IgD is present in a meager amount in the serum (0.03 mg/mL) and has an unknown function against pathogens. It is regarded as a BCR.<xref ref-type="bibr" rid="article-23392.r9">[9]</xref> IgD may play an essential role in antigen-triggered lymphocyte differentiation.<xref ref-type="bibr" rid="article-23392.r2">[2]</xref></p>
        <p>
<bold>Receptors for Immunoglobulins</bold>
</p>
        <p>Immunoglobulins should interact with receptors to fulfill various biological functions mainly expressed on mononuclear cells, mast cells, neutrophils, natural killer cells, and eosinophils. Again, binding to these receptors is essential for immunoglobulin functions. It promotes several activities, including phagocytosis of bacteria (opsonization); mast cell degranulation (as seen in type I hypersensitivity or allergic response); killing of tumors; and activation of antigen-presenting cells including macrophages and dendritic cells, which present antigens to T lymphocytes for the generation of cellular and humoral immune responses.<xref ref-type="bibr" rid="article-23392.r10">[10]</xref></p>
        <p>The following are immunoglobulin receptors:</p>
        <list list-type="order">
          <list-item>
            <p>Fc gamma RI (CD64) binds to monomeric IgG, is expressed on phagocytes, and is involved in the phagocytosis of immune complexes.</p>
          </list-item>
          <list-item>
            <p>Fc gamma RII (CD32)&#x000a0;attaches to B-cells, monocyte/macrophages (phagocytes), and granulocytes. B cells regulate cell activation in the presence of a high titer of antibodies.</p>
          </list-item>
          <list-item>
            <p>Fc gamma RIII (CD16)&#x000a0;has two types. Fc gamma RIIIa is expressed on macrophages, NK cells, and some T cells. Fc gamma RIIIb is expressed on granulocytes and has a low affinity for IgG.</p>
          </list-item>
          <list-item>
            <p>Fc epsilon RI&#x000a0;is a high-affinity IgE receptor shown on mast cells and basophils. It involves an allergic response.</p>
          </list-item>
          <list-item>
            <p>Fc epsilon RII&#x000a0; is expressed on leukocytes and lymphocytes and has homology with mannose-binding lectin.</p>
          </list-item>
        </list>
        <p>
<bold>Genetics of Immunoglobulins</bold>
</p>
        <p>The immune system can respond to many antigens by generating various immunoglobulins produced by plasma cells. V and J gene segments encode immunoglobulin light chains. The above genes, in addition to D gene segments, encode the heavy chains. The mechanisms that contribute to this great diversity of immunoglobulin specificities include somatic mutation (immunoglobulin heavy and light chain genes undergo structural modifications after antigen stimulation) and the presence of multiple V-region genes in the germline (antibody diversity also arises when numerous V genes are recombining with J and D segments). Gene conversion, recombinational inaccuracies, nucleotide addition, and assorted heavy and light chains also contribute to the diversity of immunoglobulin molecules.<xref ref-type="bibr" rid="article-23392.r11">[11]</xref><xref ref-type="bibr" rid="article-23392.r12">[12]</xref><xref ref-type="bibr" rid="article-23392.r13">[13]</xref></p>
      </sec>
      <sec id="article-23392.s4" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>Common adverse drug reactions to immunoglobulin therapy include headaches, malaise, fever, chills, and lethargy. Serious adverse drug reactions include acute kidney injury, venous thrombosis, aseptic meningitis, hemolytic anemia, and TRALI(Transfusion-related acute lung injury).<xref ref-type="bibr" rid="article-23392.r14">[14]</xref>&#x000a0;Increased risk of anaphylaxis is seen&#x000a0;in patients with IgA deficiency having common variable immunodeficiency (CVID).<xref ref-type="bibr" rid="article-23392.r15">[15]</xref></p>
      </sec>
      <sec id="article-23392.s5" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Immunoglobulins or antibodies are essential in protecting against bacteria, viruses, and fungi. When there is a deficiency of these glycoproteins, recurrent infectious diseases occur, as seen in the following antibody deficiency disorders<xref ref-type="bibr" rid="article-23392.r16">[16]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>X-linked agammaglobulinemia</p>
          </list-item>
          <list-item>
            <p>Transient hypogammaglobulinemia of infancy</p>
          </list-item>
          <list-item>
            <p>IgA deficiency</p>
          </list-item>
          <list-item>
            <p>IgG subclass deficiency</p>
          </list-item>
          <list-item>
            <p>Immunodeficiency with increased IgM</p>
          </list-item>
          <list-item>
            <p>Common variable immunodeficiency</p>
          </list-item>
        </list>
        <p>The most common immunodeficiency is Selective IgA deficiency, characterized by recurrent infections that affect the respiratory, digestive, and genitourinary systems. Recurrent pneumonia, Giardia lamblia infestation, and urinary sepsis are prevalent. The majority of patients can, however, be asymptomatic. They are at higher risk for autoimmune diseases, atopy, and anaphylaxis to IgA-containing products.<xref ref-type="bibr" rid="article-23392.r17">[17]</xref></p>
        <p>Another common problem is the transient hypogammaglobulinemia of infancy. During the first 3 to 5 months, the child is healthy but becomes sick because of a physiological deficit of immunoglobulins. This disease is characterized by recurrent bacterial infections, including pneumonia, meningitis, otitis, arthritis, and osteomyelitis. This problem diminishes once the child starts producing immunoglobulins.<xref ref-type="bibr" rid="article-23392.r18">[18]</xref></p>
        <p>X-linked agammaglobulinemia is also called Bruton agammaglobulinemia. It occurs due to a defect in Bruton Tyrosine Kinase (BTK) gene that prevents B-cell maturation. This condition is X-linked recessive and seen mostly in males. They present with recurrent bacterial and enteroviral infections after six months, once the maternal IgG is low. No B cells are seen in peripheral blood, and immunoglobulins of all classes are absent. Patients also have absent or scanty lymph nodes and tonsils. Live vaccines are contraindicated.<xref ref-type="bibr" rid="article-23392.r19">[19]</xref></p>
        <p>In common variable immunodeficiency (CVID), individuals acquire the immunodeficiency in the second or third decade of life or later. Both males and females can develop this problem.<xref ref-type="bibr" rid="article-23392.r20">[20]</xref> CVID may follow a viral infection, such as infectious mononucleosis. Giardia lamblia infestation and recurrent pyogenic infections characterize CVID. It may be due to a defect in B-cell differentiation.<xref ref-type="bibr" rid="article-23392.r21">[21]</xref> The patients have an increased risk of autoimmune disease, bronchiectasis, lymphoma, and sinopulmonary infections.</p>
        <p>Waldenstrom macroglobulinemia (WM)&#x000a0; lymphoplasmacytic lymphoma is associated with a monoclonal immunoglobulin M (IgM) protein. The presence of the monoclonal IgM protein results in hyperviscosity syndrome(IgM&#x0003e;4000 mg/dL) characterized by headache, the Raynaud phenomenon, and retinal hemorrhages.<xref ref-type="bibr" rid="article-23392.r22">[22]</xref></p>
        <p>
<bold>Laboratory Assessment of Immunoglobulins</bold>
</p>
        <p>The quantification of immunoglobulins and the study of their functions are vital for the immunodiagnosis of immunodeficiencies, autoimmunity, hypersensitivity reactions, and inflammatory disorders. The following examinations are routinely performed for the study of the behavior of antibodies:</p>
        <p>
<bold>Quantitative Serum Immunoglobulins (classes and subclasses)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>IgG</p>
          </list-item>
          <list-item>
            <p>IgM</p>
          </list-item>
          <list-item>
            <p>IgA</p>
          </list-item>
          <list-item>
            <p>IgE<xref ref-type="bibr" rid="article-23392.r16">[16]</xref></p>
          </list-item>
        </list>
        <p>This assay is used to test for the presence of immunodeficiency disorders such as those in X-linked agammaglobulinemia. There are insufficient amounts of all classes of immunoglobulins, or they are absent. The presence of low IgA may be associated with recurrent diarrhea and lung and sinus infections. Low IgG is associated with pyogenic infections, and a high IgE may be found in parasitic infections.</p>
        <p>
<bold>IgG Antibodies (post-immunization)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Tetanus toxoid</p>
          </list-item>
          <list-item>
            <p>Diphtheria toxoid</p>
          </list-item>
          <list-item>
            <p>Pneumococcal polysaccharide</p>
          </list-item>
          <list-item>
            <p>Polio</p>
          </list-item>
        </list>
        <p>This assay evaluates the quality of the immune response after vaccination. In healthy individuals, there is at least a 1:16 titer of antibody.</p>
        <p>
<bold>IgG Antibodies (post-exposure)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Measles</p>
          </list-item>
          <list-item>
            <p>Varicella-Zoster</p>
          </list-item>
        </list>
        <p>This test evaluates the production of antibodies against antigens after the infectious disease has occurred.</p>
        <p>
<bold>Detection of Isohemagglutinins (IgM)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Anti-type A blood</p>
          </list-item>
          <list-item>
            <p>Anti-type B blood</p>
          </list-item>
        </list>
        <p>Isohemagglutinins are IgM antibodies the immune system produces in response to bacterial antigens in the digestive system. It has been shown that their titers may be below 1:4 in antibody deficiency disorders.</p>
        <p>
<bold>Other Assays</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Test for heterophile antibody to measure the presence of antibodies against Epstein-Barr virus</p>
          </list-item>
          <list-item>
            <p>Serum protein electrophoresis evaluates the level of antibodies qualitatively. For example, multiple myeloma shows a monoclonal peak in the gamma region of the electrophoresis that is consistent with a monoclonal antibody.</p>
          </list-item>
          <list-item>
            <p>Rheumatoid factor is an IgM antibody against the IgG Fc region and is an important seromarker of rheumatoid arthritis (RA).<xref ref-type="bibr" rid="article-23392.r23">[23]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Clinical Use of Immunoglobulins</bold>
</p>
        <p>Immunoglobulins or antibodies can be used as a form of immunotherapy. Like drugs, they are prepared from a pool of blood donated at blood collection centers and processed through fractionation to separate the protein fraction from the cellular component. The purified immunoglobulin can treat many immunological problems, including antibody deficiencies, severe combined immunodeficiency disorders (SCID), multiple sclerosis, myasthenia gravis, Kawasaki disease, systemic lupus erythematosus (SLE), organ transplantations, and many others.<xref ref-type="bibr" rid="article-23392.r24">[24]</xref><xref ref-type="bibr" rid="article-23392.r25">[25]</xref><xref ref-type="bibr" rid="article-23392.r26">[26]</xref><xref ref-type="bibr" rid="article-23392.r27">[27]</xref>&#x000a0;In addition, therapy with&#x000a0;IVIg started within two weeks from onset hastens recovery in patients with&#x000a0;Guillain-Barr&#x000e9; syndrome (GBS).<xref ref-type="bibr" rid="article-23392.r28">[28]</xref></p>
      </sec>
      <sec id="article-23392.s6" sec-type="Other Issues">
        <title>Other Issues</title>
        <p>The role of Immunoglobulin D has not been clear. However, recent research suggests&#x000a0;Secreted Immunoglobulin D improves mucosal homeostasis and immune system vigilance by providing myeloid cells such as basophils and mast cells with IgD antibodies reactive against mucosal antigens against pathogenic microorganisms. However, additional research is needed to understand the precise function of immunoglobulin D.<xref ref-type="bibr" rid="article-23392.r9">[9]</xref></p>
        <p>In a study, distinct immunoglobulin patterns predicted the risk of developing post-acute COVID-19 syndrome(PACS). Researchers observed decreased IgM, unaltered IgG1, and decreased IgG3 in patients with PACS. In addition. Evaluation of changes in COVID-19 patients at primary infection, six-month, and one-year follow-up, indicated that these total serum Ig concentrations remained steady over time. In summary, patients with either low IgM or low IgG3 had an increased risk of acquiring PACS, whereas patients with both high IgM and high IgG3 were less likely to develop PACS.<xref ref-type="bibr" rid="article-23392.r29">[29]</xref></p>
      </sec>
      <sec id="article-23392.s7" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Managing patients with immunoglobulin deficiencies involves an interprofessional team that includes nurses, clinicians, and pharmacists. Many of these patients are prone to infections and opportunistic organisms; hence surveillance and close monitoring of the patient is vital.&#x000a0;Immunologists, transplant specialists, geneticists, and hematologists from&#x000a0; NIH collaborate in an interprofessional manner for the Blood and Immune Deficiency&#x02013;Cellular Therapy Program (BID&#x02013;CTP). These clinicians deliver state-of-the-art and experimental care to patients with rare blood and immune system diseases through an integrated and interprofessional approach to evaluating, treating, and monitoring patients.</p>
        <p>Similarly,&#x000a0;PIDTC (Primary Immune Deficiency Treatment Consortium)&#x000a0; is a network of 33 centers in North America that explore the management of severe primary immunodeficiency diseases (PID). PIDTC evaluates the natural history of patients treated for Severe Combined Immunodeficiency (SCID), Wiskott-Aldrich Syndrome, and Chronic Granulomatous Disease through retrospective, prospective and cross-sectional studies. In addition, the PIDTC has interprofessional collaborative partnerships with European and international colleagues and works with patient advocacy groups to promote community awareness.<xref ref-type="bibr" rid="article-23392.r30">[30]</xref></p>
      </sec>
      <sec id="article-23392.s8" sec-type="Nursing, Allied Health, and Interprofessional Team Interventions">
        <title>Nursing, Allied Health, and Interprofessional Team Interventions</title>
        <p>Clinical nurse specialists (CNS) interventions and other healthcare professionals can reduce the risk of adverse events associated with immunoglobulin therapy. Providing adequate hydration before IVIG administration can reduce the risk of developing an acute kidney injury. Nursing interventions for&#x000a0;post-infusion headaches are to decrease the infusion rate, and administering premedication with NSAIDs /acetaminophen can be helpful.<xref ref-type="bibr" rid="article-23392.r31">[31]</xref> If there is a concern regarding the development of aseptic meningitis, the concerned clinician should be contacted immediately, and switching to subcutaneous immunoglobulin (SCIg) is required.<xref ref-type="bibr" rid="article-23392.r32">[32]</xref></p>
      </sec>
      <sec id="article-23392.s9" sec-type="Nursing, Allied Health, and Interprofessional Team Monitoring">
        <title>Nursing, Allied Health, and Interprofessional Team Monitoring</title>
        <p>Hypotension and anaphylaxis are known complications of immunoglobulin therapy. Hence, healthcare providers should monitor vital signs,&#x000a0;shortness of breath, and urticaria.&#x000a0;Transfusion-related acute lung injury (TRALI) can occur within six hours of&#x000a0;transfusion. Monitor for clinical signs and symptoms such as hypotension, vomiting,&#x000a0; dyspnea, and&#x000a0;hypoxemia, as TRALI requires immediate workup, cessation of infusion, and supportive treatment with close monitoring.<xref ref-type="bibr" rid="article-23392.r14">[14]</xref></p>
      </sec>
      <sec id="article-23392.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23392&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23392">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23392/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23392">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-23392.s11">
        <title>References</title>
        <ref id="article-23392.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burton</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Antibody: the flexible adaptor molecule.</article-title>
            <source>Trends Biochem Sci</source>
            <year>1990</year>
            <month>Feb</month>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>64</fpage>
            <page-range>64-9</page-range>
            <pub-id pub-id-type="pmid">2186517</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23392.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goding</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Allotypes of IgM and IgD receptors in the mouse: a probe for lymphocyte differentiation.</article-title>
            <source>Contemp Top Immunobiol</source>
            <year>1978</year>
            <volume>8</volume>
            <fpage>203</fpage>
            <page-range>203-43</page-range>
            <pub-id pub-id-type="pmid">357078</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23392.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vasilev</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Smales</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Schillberg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schiermeyer</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Developments in the production of mucosal antibodies in plants.</article-title>
            <source>Biotechnol Adv</source>
            <year>2016</year>
            <season>Mar-Apr</season>
            <volume>34</volume>
            <issue>2</issue>
            <fpage>77</fpage>
            <page-range>77-87</page-range>
            <pub-id pub-id-type="pmid">26626615</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23392.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Palmeira</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Quinello</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Silveira-Lessa</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Zago</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Carneiro-Sampaio</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>IgG placental transfer in healthy and pathological pregnancies.</article-title>
            <source>Clin Dev Immunol</source>
            <year>2012</year>
            <volume>2012</volume>
            <fpage>985646</fpage>
            <pub-id pub-id-type="pmid">22235228</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23392.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Daha</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>van Kooten</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Role of complement in IgA nephropathy.</article-title>
            <source>J Nephrol</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>29</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-4</page-range>
            <pub-id pub-id-type="pmid">26567162</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23392.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maurer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Altrichter</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schmetzer</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Scheffel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Church</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Metz</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Immunoglobulin E-Mediated Autoimmunity.</article-title>
            <source>Front Immunol</source>
            <year>2018</year>
            <volume>9</volume>
            <fpage>689</fpage>
            <pub-id pub-id-type="pmid">29686678</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23392.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mukai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Starkl</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Marichal</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Galli</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>IgE and mast cells in host defense against parasites and venoms.</article-title>
            <source>Semin Immunopathol</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>38</volume>
            <issue>5</issue>
            <fpage>581</fpage>
            <page-range>581-603</page-range>
            <pub-id pub-id-type="pmid">27225312</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23392.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schwartz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Eberle</surname>
                <given-names>JU</given-names>
              </name>
              <name>
                <surname>Voehringer</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Basophils in inflammation.</article-title>
            <source>Eur J Pharmacol</source>
            <year>2016</year>
            <month>May</month>
            <day>05</day>
            <volume>778</volume>
            <fpage>90</fpage>
            <page-range>90-5</page-range>
            <pub-id pub-id-type="pmid">25959388</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23392.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gutzeit</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cerutti</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The enigmatic function of IgD: some answers at last.</article-title>
            <source>Eur J Immunol</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>48</volume>
            <issue>7</issue>
            <fpage>1101</fpage>
            <page-range>1101-1113</page-range>
            <pub-id pub-id-type="pmid">29733429</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23392.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Engels</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wienands</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Memory control by the B cell antigen receptor.</article-title>
            <source>Immunol Rev</source>
            <year>2018</year>
            <month>May</month>
            <volume>283</volume>
            <issue>1</issue>
            <fpage>150</fpage>
            <page-range>150-160</page-range>
            <pub-id pub-id-type="pmid">29664567</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23392.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wienands</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Engels</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Control of memory B cell responses by extrinsic and intrinsic mechanisms.</article-title>
            <source>Immunol Lett</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>178</volume>
            <fpage>27</fpage>
            <page-range>27-30</page-range>
            <pub-id pub-id-type="pmid">27345519</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23392.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lewis</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Evolution of immunoglobulin and T-cell receptor gene assembly.</article-title>
            <source>Ann N Y Acad Sci</source>
            <year>1999</year>
            <month>May</month>
            <day>18</day>
            <volume>870</volume>
            <fpage>58</fpage>
            <page-range>58-67</page-range>
            <pub-id pub-id-type="pmid">10415473</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23392.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lewis</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>GE</given-names>
              </name>
            </person-group>
            <article-title>The origins of V(D)J recombination.</article-title>
            <source>Cell</source>
            <year>1997</year>
            <month>Jan</month>
            <day>24</day>
            <volume>88</volume>
            <issue>2</issue>
            <fpage>159</fpage>
            <page-range>159-62</page-range>
            <pub-id pub-id-type="pmid">9008155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23392.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Adverse Effects of Immunoglobulin Therapy.</article-title>
            <source>Front Immunol</source>
            <year>2018</year>
            <volume>9</volume>
            <fpage>1299</fpage>
            <pub-id pub-id-type="pmid">29951056</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23392.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Anaphylaxis to IVIG.</article-title>
            <source>Arch Immunol Ther Exp (Warsz)</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>65</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-19</page-range>
            <pub-id pub-id-type="pmid">27412077</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23392.r16">
          <label>16</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Justiz Vaillant</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Ramphul</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Antibody Deficiency Disorder</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>23</day>
            <pub-id pub-id-type="pmid">29939682</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23392.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stonebraker</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Farrugia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gathmann</surname>
                <given-names>B</given-names>
              </name>
              <collab>ESID Registry Working Party</collab>
              <name>
                <surname>Orange</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Modeling primary immunodeficiency disease epidemiology and its treatment to estimate latent therapeutic demand for immunoglobulin.</article-title>
            <source>J Clin Immunol</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>34</volume>
            <issue>2</issue>
            <fpage>233</fpage>
            <page-range>233-44</page-range>
            <pub-id pub-id-type="pmid">24338563</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23392.r18">
          <label>18</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Justiz Vaillant</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Qurie</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Immunodeficiency</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">29763203</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23392.r19">
          <label>19</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Taneja</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Muco</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chhabra</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Bruton Agammaglobulinemia</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>9</month>
            <day>4</day>
            <pub-id pub-id-type="pmid">28846295</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23392.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saikia</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Common Variable Immunodeficiency.</article-title>
            <source>Indian J Pediatr</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>83</volume>
            <issue>4</issue>
            <fpage>338</fpage>
            <page-range>338-44</page-range>
            <pub-id pub-id-type="pmid">26868026</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23392.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Song</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lleo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>GX</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Bowlus</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Gershwin</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>PSC</given-names>
              </name>
            </person-group>
            <article-title>Common Variable Immunodeficiency and Liver Involvement.</article-title>
            <source>Clin Rev Allergy Immunol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>55</volume>
            <issue>3</issue>
            <fpage>340</fpage>
            <page-range>340-351</page-range>
            <pub-id pub-id-type="pmid">28785926</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23392.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gertz</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Waldenstr&#x000f6;m macroglobulinemia: 2021 update on diagnosis, risk stratification, and management.</article-title>
            <source>Am J Hematol</source>
            <year>2021</year>
            <month>Feb</month>
            <day>01</day>
            <volume>96</volume>
            <issue>2</issue>
            <fpage>258</fpage>
            <page-range>258-269</page-range>
            <pub-id pub-id-type="pmid">33368476</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23392.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kanmert</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kastbom</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Almroth</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Skogh</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Enander</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wetter&#x000f6;</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>IgG rheumatoid factors against the four human Fc-gamma subclasses in early rheumatoid arthritis (the Swedish TIRA project).</article-title>
            <source>Scand J Immunol</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>75</volume>
            <issue>1</issue>
            <fpage>115</fpage>
            <page-range>115-9</page-range>
            <pub-id pub-id-type="pmid">21916920</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23392.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vince</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mouillot</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Malphettes</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Limou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Boutboul</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Guignet</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bertrand</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Pellet</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gourraud</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Debr&#x000e9;</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Oksenhendler</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Th&#x000e9;odorou</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Fieschi</surname>
                <given-names>C</given-names>
              </name>
              <collab>DEFI Study Group</collab>
            </person-group>
            <article-title>Genetic screening of male patients with primary hypogammaglobulinemia can guide diagnosis and clinical management.</article-title>
            <source>Hum Immunol</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>79</volume>
            <issue>7</issue>
            <fpage>571</fpage>
            <page-range>571-577</page-range>
            <pub-id pub-id-type="pmid">29709555</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23392.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ius</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Verboom</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sommer</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Poyanmehr</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Knoefel</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Salman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kuehn</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Avsar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Siemeni</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Erdfelder</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hallensleben</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Boethig</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Schwerk</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mueller</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Welte</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Falk</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Haverich</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tudorache</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Warnecke</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Preemptive treatment of early donor-specific antibodies with IgA- and IgM-enriched intravenous human immunoglobulins in lung transplantation.</article-title>
            <source>Am J Transplant</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>18</volume>
            <issue>9</issue>
            <fpage>2295</fpage>
            <page-range>2295-2304</page-range>
            <pub-id pub-id-type="pmid">29719115</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23392.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Han</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Immune modulation of i.v. immunoglobulin in women with reproductive failure.</article-title>
            <source>Reprod Med Biol</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>17</volume>
            <issue>2</issue>
            <fpage>115</fpage>
            <page-range>115-124</page-range>
            <pub-id pub-id-type="pmid">29692668</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23392.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farmakidis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pasnoor</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dimachkie</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Barohn</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Myasthenia Gravis.</article-title>
            <source>Neurol Clin</source>
            <year>2018</year>
            <month>May</month>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>311</fpage>
            <page-range>311-337</page-range>
            <pub-id pub-id-type="pmid">29655452</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23392.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hughes</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Swan</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>van Doorn</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Intravenous immunoglobulin for Guillain-Barr&#x000e9; syndrome.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2014</year>
            <month>Sep</month>
            <day>19</day>
            <volume>2014</volume>
            <issue>9</issue>
            <fpage>CD002063</fpage>
            <pub-id pub-id-type="pmid">25238327</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23392.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cervia</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zurbuchen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Taeschler</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ballouz</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Menges</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hasler</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Adamo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Raeber</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>B&#x000e4;chli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rudiger</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>St&#x000fc;ssi-Helbling</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Huber</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Nilsson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Held</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Puhan</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Boyman</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome.</article-title>
            <source>Nat Commun</source>
            <year>2022</year>
            <month>Jan</month>
            <day>25</day>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>446</fpage>
            <pub-id pub-id-type="pmid">35078982</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23392.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Griffith</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Cowan</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Notarangelo</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Kohn</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Puck</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Pai</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Ballard</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Bleesing</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Boyle</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brower</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Buckley</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>van der Burg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Burroughs</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Candotti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cant</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Chatila</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cunningham-Rundles</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dinauer</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Dvorak</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Filipovich</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Fleisher</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Bobby Gaspar</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gungor</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Haddad</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hovermale</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hurley</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hurley</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Iyengar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Logan</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Long-Boyle</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Malech</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>McGhee</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Modell</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Modell</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ochs</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>O'Reilly</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Parkman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rawlings</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Routes</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Shearer</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Small</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Szabolcs</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Thrasher</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Torgerson</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Veys</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Weinberg</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zuniga-Pflucker</surname>
                <given-names>JC</given-names>
              </name>
              <collab>workshop participants</collab>
            </person-group>
            <article-title>Primary Immune Deficiency Treatment Consortium (PIDTC) report.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>133</volume>
            <issue>2</issue>
            <fpage>335</fpage>
            <page-range>335-47</page-range>
            <pub-id pub-id-type="pmid">24139498</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23392.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thornby</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Henneman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Evidence-based strategies to reduce intravenous immunoglobulin-induced headaches.</article-title>
            <source>Ann Pharmacother</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>49</volume>
            <issue>6</issue>
            <fpage>715</fpage>
            <page-range>715-26</page-range>
            <pub-id pub-id-type="pmid">25757469</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23392.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jain</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aggarwal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kookna</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Acute aseptic meningitis due to intravenous immunoglobulin therapy in Guillain-Barr&#x000e9; syndrome.</article-title>
            <source>Oxf Med Case Reports</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>2014</volume>
            <issue>7</issue>
            <fpage>132</fpage>
            <page-range>132-4</page-range>
            <pub-id pub-id-type="pmid">25988056</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
